ESTRO 35 2016 S543 ________________________________________________________________________________ radiotherapy (3D-CRT) techniques and compared with IMRT plans. The 3D-CRT plans were prepared using 3-4 fields and IMRT plans consisted of 7-8 fields. The primary objective was to treat the planning target volume and to minimize the dose to organs at risk (OAR). Volumetric analysis, target coverage and conformity of prescribed doses were used in plan comparison.
Purpose or Objective:
There is little consensus about the optimal treatment for low-grade glioma (LGG), and the clinical management of LGG is one of the most controversial areas in neurooncology. Radiation therapy is one option for treatment of patients with LGG whereas other options include postoperative observation. The aim of the study is to report the long-term follow-up of a cohort of adult patients with LGG post-operatively irradiated in one institution, and to identify prognostic factors for progression free survival. Between 1975 and 2005, 180 patients with LGG (WHO II) received postoperative irradiation after non radical (subtotal or partial) excision. Patients had to be 18 years of age or older, and have histologic proof of supratentorial fibrillary (FA), protoplasmic (PA) or gemistocytic astrocytoma (GA). Radiotherapy was given within 3 to 10 weeks after surgery. The treatment fields were localized and included the preoperative tumor volume, with a 1-2 cm margin, treated to a total dose of 50 to 60 Gy in 25 to 30 fractions over 5 to 6 weeks.
Material and Methods:
Results: Actuarial ten-year progression free survival ( APFS) in the whole group was 19% . The worse prognosis was reserved for patients with GA. Ten-year APFS rates for GA, PA and FA were 10%, 18% and 22% respectively.
Conclusion:
The findings from our long-term cohort of 180 patients with LGG confirmed by uni-and multivariate analysis demonstrated that only astrocytoma histology significantly determined the prognosis. The best survival is reserved for patients with the fibrillary variant, and the worst for the gemistocytic one.
EP-1134
Proton therapy re-irradiation for large-volume recurrent high-grade gliomas D. Amelio Purpose or Objective: To report preliminary results of reirradiation with proton therapy (PT) for large-volume recurrent high-grade gliomas (rHGG).
Material and Methods:
Between January and September 2015 eight patients (pts) with rHGG (7 glioblastoma -GBM, 1 anaplastic oligodendroglioma -AOD) were re-irradiated with PT. Age at re-irradiation was between 40 and 64 years while Karnofsky performance status was 60-100%. Minimum time between prior radiotherapy and PT was 8 months. Target definition was based on CT, MR, and 18F-DOPA PET imaging. GTV included any area of contrast enhancement at MR imaging after contrast medium administration plus any uptake regions at PET imaging. CTV was generated by adding to GTV a 3-mm uniform margin manually corrected in proximity of anatomical barriers. CTV was expanded by 4 mm to create PTV. PTV volume varied between 55 and 260 cc. The patient with AOD received 50.4 GyRBE in 28 fractions (fx) while GBM pts 36 GyRBE in 18 fx. Four GBM pts also received concomitant temozolomide (75 mg/m2/day, 7 days/week). All pts were treated with active beam scanning PT using 2-3 fields with single field optimization technique.
Results: All pts completed the treatment without breaks. Registered acute side effects (according to Common Terminology Criteria for Adverse Events versione 4.0) include skin erythema with pruritus, alopecia, fatigue, conjunctivitis, and headache. All the side effects were grade 1 or 2. There were no grade 3 or higher toxicities. One patient developed grade 1 neutropenia. Three pts started PT under steroids (2-8 mg/day); two of them reduced the dose during PT, one kept the same steroids dose. None of remaining pts needed steroids therapy. During follow-up two pts developed radionecrosis (diagnosed at imaging) with mild symptoms controlled with steroids. All pts are alive. Four pts have stable disease one months after PT, three pts have stable disease three months after PT, and one pts progressed five months after PT.
Conclusion:
PT re-irradiation of large volume rHGG is feasible and safe even with concomitant chemotherapy administration. Longer follow-up is necessary to assess definitive efficacy.
EP-1135
Hypofractioned Stereotactic Radiation Therapy for cavernous sinus meningiomas F. Meniai-Merzouki S544 ESTRO 35 2016 _____________________________________________________________________________________________________ with median follow up of 18 months (6-40 months). Six patients had prior surgical resection of tumor, 12 received treatment as first line. The majority (60 %) of lesions were close to the optic pathway with median values for GTV volume was 9,4 cm3 (0,38-55,66 cm3). The control rates at tow years were favorable with stable disease in 100 % patients, vision was preserved and improved symptoms in 65% patients. We observed no grade 3 or 4 toxicity. The most frequent being grade 1 retro-orbital pain (20%). No late toxicity was reported and no death during the follow -up period.
Conclusion:
Robotic Hypo-fractionated stereotactic radiotherapy for Cavernous sinus meningioma is feasible and provides a satisfactory local control with acceptable tolerance, either as a first line treatment or as adjuvant to incomplete surgery or relapse. Although this type of tumor has a slow evolution, extended follow-up is mandatory. Purpose or Objective: Until the advent of stereotactic radiotherapy, the main treatment option consisted of cranial radiation for palliation. With a more radical intent, and only in selected patients, surgical resection and adjuvant radiotherapy was indicated later. The purpose of this study is to evaluate the results obtained after treatment with singlesession radiosurgery.
EP-1136 Treatment with radiosurgery (stereotactic radiotherapy) in single session in brain metastases

Material and Methods:
Between 2002 and 2014, has collected a representative sample of 592 patients with histological diagnosis of brain metastases, of which 340 were men and 252 women. The average age in this group was 55.67 years (14-82 years) and with a KPS of 90 in 58.3% of patients. The most common location of these was lung 51%, followed by 17.1% mom. The most frequent pathological study adenocarcinoma was 23.5%, followed by squamous 10.6%. In most 63.2% no surgery was performed. The most common site was the frontal 24.4%. All patients were treated with radiosurgery (stereotactic radiotherapy) single session with a median dose of treatment of 18 Gy.
Results:
With a median follow-up of 7 months, median survival was 14.23 months in a range of 0-117 months. In terms of toxicity, only 3.5% of the presented radiation necrosis (21 patients), while the cerebral edema was reported in 10.8% (64 patients).
Conclusion:
The single session radiosurgery is a conservative but with a radical purpose, offering technical and few side effects is very convenient for the patient. 
EP-1137 Volumetric Modulated Arc Therapy (VMAT) and simultaneus boost for brain metastases patients
Material and Methods:
Between November 2010 and March 2015, 26 patients with 1-3 brain metastases were treated with SIB-IMRT in the Department of Radiation Oncology at V. Fazzi Hospital (maximum diameter of largest metastasis ≤ 3 cm, KPS ≥ 70, RPA < III). Mean age was 61 ± 7.5 years. Patients were neurologically stable. Extracranial disease well-controlled (6-month estimated median life expectancy). Patients will undergo contrast-enhanced TC scan of the brain for radiotherapy planning purposes. The macroscopic (gross) tumor volume (GTV) was drawn on the MRI images. The prescription isodose line was generally 3 mm larger than the GTV. Patients will be treated with WBRT/SIB using VMAT, delivering a total of 30 Gy in 10 fractions to the whole brain and SIB doses to brain metastases were 40 Gy to lesions >or= 2.0 cm and 50 Gy to lesions <2.0 cm in diameter, delivered once daily on working days. Following therapy completion, patients will be seen every 3 months for the 1st year, then every 6 months thereafter. Patients will have MRI brain at 3 months and 1 year, and every 6 months after the first year. Any toxicity was recorded according to the RTOG.
Results:
The median follow-up interval was 9 months (range, 2 months-16 months). The median overall survival time was 11 months, and 3 of patients died of disease progression. The 6-month overall survival was 91%. After SIB-IMRT treatment of 42 brain lesions, 35 lesions demonstrated complete responses, 5 lesions demonstrated partial responses, 2 lesion demonstrated stable disease. Actuarial local tumor control rates at 6 months, 1 year and 2 years were 93.9, 82% and 54%, respectively. Thirty-eight patients did not have any adverse events >grade1. The majority of common adverse events were grade 2 headaches (4 patients), grade 2 motor neuropathy (2 patients), and grade 2 lethargy (2 patient). One patient developed a grade 3 headache 5 months after receiving SIB-IMRT.
Conclusion:
The delivery of 40/50 Gy in 10 fractions to 1 -3 BM using VMAT provides a high level of tumor control with minimal toxicity. Therefore, we believe there is a need for a larger prospective study to establish dosing guidelines for SIB-IMRT and to pave the way for a randomized trial to compare SRS/STS plus WBRT with this approach. 
